Le Ngoc Ha, Le Quoc Khanh, Ngo Thi Minh Hanh, Hyo Jung Seo, Mai Hong Son
{"title":"甲状腺乳头状癌脑转移的筛查和治疗:一个病例系列。","authors":"Le Ngoc Ha, Le Quoc Khanh, Ngo Thi Minh Hanh, Hyo Jung Seo, Mai Hong Son","doi":"10.1186/s13044-023-00146-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The brain metastasis from differentiated thyroid carcinoma (DTC) is a rare condition and its prognosis is poor. The standard protocol for screening and treatment of patients with brain metastases from papillary thyroid cancer (PTC) remains controversial. This report aims to share the experience of a single center in the management of brain metastases from DTC.</p><p><strong>Material and methods: </strong>Five patients with brain metastases were identified from 5000 patients with DTC attending the department of nuclear medicine, Hospital 108 between 2016 to 2022. The statistical software Statistical Package for Social Sciences (SPSS) 20.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the data.</p><p><strong>Results: </strong>Five patients with brain metastases from DTC were revealed by MRI, <sup>18</sup>F-FDG PET/CT with contrast enhancement, and <sup>131</sup>I-SPECT/CT. The median time of overall survival (OS) was 15 months, ranging from 10 to 65 months. Two out of the five patients underwent surgery, and futher 2 patients were treated with stereotactic surgery (SRS). All patients are still alive.</p><p><strong>Conclusions: </strong>Brain metastases from DTC are rare. MRI is the preferred imaging mobility to screen brain lesions in DTC. The primary treatment modalities are surgery and SRS.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832656/pdf/","citationCount":"2","resultStr":"{\"title\":\"Screening and treatment of brain metastasis from papillary thyroid carcinoma: a case series.\",\"authors\":\"Le Ngoc Ha, Le Quoc Khanh, Ngo Thi Minh Hanh, Hyo Jung Seo, Mai Hong Son\",\"doi\":\"10.1186/s13044-023-00146-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The brain metastasis from differentiated thyroid carcinoma (DTC) is a rare condition and its prognosis is poor. The standard protocol for screening and treatment of patients with brain metastases from papillary thyroid cancer (PTC) remains controversial. This report aims to share the experience of a single center in the management of brain metastases from DTC.</p><p><strong>Material and methods: </strong>Five patients with brain metastases were identified from 5000 patients with DTC attending the department of nuclear medicine, Hospital 108 between 2016 to 2022. The statistical software Statistical Package for Social Sciences (SPSS) 20.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the data.</p><p><strong>Results: </strong>Five patients with brain metastases from DTC were revealed by MRI, <sup>18</sup>F-FDG PET/CT with contrast enhancement, and <sup>131</sup>I-SPECT/CT. The median time of overall survival (OS) was 15 months, ranging from 10 to 65 months. Two out of the five patients underwent surgery, and futher 2 patients were treated with stereotactic surgery (SRS). All patients are still alive.</p><p><strong>Conclusions: </strong>Brain metastases from DTC are rare. MRI is the preferred imaging mobility to screen brain lesions in DTC. The primary treatment modalities are surgery and SRS.</p>\",\"PeriodicalId\":39048,\"journal\":{\"name\":\"Thyroid Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832656/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thyroid Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s13044-023-00146-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13044-023-00146-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 2
摘要
背景:分化型甲状腺癌(DTC)脑转移是一种罕见且预后较差的疾病。筛查和治疗甲状腺乳头状癌(PTC)脑转移患者的标准方案仍然存在争议。本报告旨在分享单一中心治疗DTC脑转移的经验。材料与方法:从2016年至2022年在108医院核医学科就诊的5000例DTC患者中筛选出5例脑转移患者。采用统计软件SPSS 20.0 (SPSS Inc., Chicago, IL, USA)对数据进行分析。结果:5例DTC脑转移灶经MRI、18F-FDG PET/CT增强扫描及131I-SPECT/CT扫描发现。中位总生存期(OS)为15个月,范围为10 ~ 65个月。5例患者中2例接受手术治疗,2例接受立体定向手术(SRS)治疗。所有病人都还活着。结论:DTC的脑转移是罕见的。MRI是筛查DTC脑病变的首选影像学手段。主要的治疗方式是手术和SRS。
Screening and treatment of brain metastasis from papillary thyroid carcinoma: a case series.
Background: The brain metastasis from differentiated thyroid carcinoma (DTC) is a rare condition and its prognosis is poor. The standard protocol for screening and treatment of patients with brain metastases from papillary thyroid cancer (PTC) remains controversial. This report aims to share the experience of a single center in the management of brain metastases from DTC.
Material and methods: Five patients with brain metastases were identified from 5000 patients with DTC attending the department of nuclear medicine, Hospital 108 between 2016 to 2022. The statistical software Statistical Package for Social Sciences (SPSS) 20.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the data.
Results: Five patients with brain metastases from DTC were revealed by MRI, 18F-FDG PET/CT with contrast enhancement, and 131I-SPECT/CT. The median time of overall survival (OS) was 15 months, ranging from 10 to 65 months. Two out of the five patients underwent surgery, and futher 2 patients were treated with stereotactic surgery (SRS). All patients are still alive.
Conclusions: Brain metastases from DTC are rare. MRI is the preferred imaging mobility to screen brain lesions in DTC. The primary treatment modalities are surgery and SRS.